Characterization of GLP-1 effects on β-cell function after meal ingestion in humans

Diabetes Care

Volumn 26, Issue 10, 2003, Pages 2860-2864

  Ahrén, Bo ^a   Holst, Jens J ^b   Mari, Andrea ^c  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; SODIUM CHLORIDE;

AGED; ARTICLE; BODY MASS; CASE REPORT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL;

AGED; BLOOD GLUCOSE; C-PEPTIDE; EATING; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; ISLETS OF LANGERHANS; PEPTIDE FRAGMENTS; POSTPRANDIAL PERIOD; PROTEIN PRECURSORS;

EID: 0141446274     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.10.2860     Document Type: Article

References (22)

1. Ahrén B: Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes. Bioessays 20:642-651, 1998
2. Kieffer TJ, Habener JG: The glucagon-like peptides. Endocr Rev 20:876-913, 1999
3. Drucker DJ: Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122:531-544, 2002
4. Doyle ME, Egan JM: Glucagon-like peptide-1. Recent Prog Horm Res 56:377-399, 2001.
5. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Ørskov C, Ritzel R, Schmiegel WH: Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273:E981-E988, 1997
6. Näslund E, Bogefors J, Skogar S, Grybäck P, Jacobsson H, Holst JJ, Hellström P: GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 277:R910-R916, 1999
7. Gutniak M, Ørskov C, Holst JJ, Ahrén B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322, 1992
8. Nathan DM, Schrieber E, Fogel H, Mojsov S, Habener JF: Insulinotropic action of glucagon-like peptide-I-(7-37) in diabetic and non-diabetic subjects. Diabetes Care 15:270-276, 1992
9. Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC: Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1(7-36)amide in patients with NIDDM. Diabetes 45:1524-1534, 1996
10. Gutniak MK, Larsson H, Sanders SW, Juneskans O, Holst JJ, Ahrén B: GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions. Diabetes Care 20:1874-1879, 1997
11. Gutniak MK, Svartberg J, Hellström PM, Holst JJ, Adner N, Ahrén B: Antidiabetogenic action of GLP-1 related to administration relative to meal intake in subjects with type 2 diabetes. J Intern Med 250:81-87, 2001
12. 2+ release in INS-1 pancreatic β cells. J Physiol 546: 175-189, 2003
13. Kreymann B, Ghatei MA, Williams G, Bloom SR: Glucagon-like peptide 1 (7-36): a physiological incretin in man. Lancet 2:1300-1304, 1987
14. D'Alessio DA, Kahn SE, Lausner CR, Ensinck JW: Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93:2263-2266, 1994
15. Nauck M, Bartels E, Ørskov C, Ebert R, Creutzfeldt W: Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 (7-36 amide) infused at near-physiological insulinotropic and hormone and glucose concentrations. J Clin Endocrinol Metab 76:912-917, 1993
16. Kjems LL, Holst JJ, Volund A, Madsbad S: The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52:380-386, 2003
17. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E: Meal and oral glucose tests for assessment of β-cell function: modeling analysis in normal subjects. Am J Physiol 283:E1159-E1166, 2002
18. Mari A, Tura A, Gastaldelli A, Ferrannini E: Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes 51:S221-S226, 2002
19. Larsson H, Ahrén B, Lindgärde F, Berglund G: Fasting blood glucose in determining prevalence of diabetes in a large, homogenous population of Caucasian middle-aged women. J Intern Med 235: 537-541, 1995
20. Gutniak MK, Larsson H, Heiber SJ, Juneskans OT, Holst JJ, Ahrén B: Potential therapeutic levels of glucagon-like peptide-1 achieved in humans by a buccal tablet. Diabetes Care 19:843-848, 1996
21. Deacon CF, Johnsen AH, Holst JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957, 1995
22. Van Cauter E, Mestrez F, Sturis J, Polonsky KS: Estimation of insulin secretion rates from C-peptide levels: comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41: 368-377, 1992